GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice
-
Published:2016-02
Issue:
Volume:299
Page:105-110
-
ISSN:0166-4328
-
Container-title:Behavioural Brain Research
-
language:en
-
Short-container-title:Behavioural Brain Research
Author:
Rajagopal Lakshmi,
Burgdorf Jeffrey S.,
Moskal Joseph R.,
Meltzer Herbert Y.ORCID
Subject
Behavioral Neuroscience
Reference39 articles.
1. GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists;Moskal;Expert Opin. Invest. Drugs,2014
2. Randomized proof of concept trial of GLYX-13, an N-methyl-d-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent;Preskorn;J. Psychiatr. Pract.,2015
3. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder;Niciu;J. Neural Transm.,2014
4. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses;Krystal;Arch. Gen. Psychiatry,1994
5. NMDA receptor regulation of memory and behavior in humans;Newcomer;Hippocampus,2001
Cited by
43 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献